Abbott Laboratories (NYSE:ABT) Shares Acquired by Delaney Dennis R

Delaney Dennis R boosted its holdings in Abbott Laboratories (NYSE:ABT) by 1.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 60,571 shares of the healthcare product maker’s stock after acquiring an additional 985 shares during the quarter. Abbott Laboratories comprises about 3.6% of Delaney Dennis R’s investment portfolio, making the stock its 10th biggest holding. Delaney Dennis R’s holdings in Abbott Laboratories were worth $6,851,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Abbott Laboratories by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 168,645,397 shares of the healthcare product maker’s stock worth $19,075,481,000 after acquiring an additional 739,260 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Abbott Laboratories by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 35,668,834 shares of the healthcare product maker’s stock valued at $4,023,027,000 after purchasing an additional 765,636 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Abbott Laboratories by 2.3% during the fourth quarter. Wellington Management Group LLP now owns 26,392,302 shares of the healthcare product maker’s stock valued at $2,985,233,000 after buying an additional 581,325 shares in the last quarter. Norges Bank acquired a new position in shares of Abbott Laboratories in the 4th quarter valued at about $2,373,461,000. Finally, Charles Schwab Investment Management Inc. increased its stake in Abbott Laboratories by 2.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 12,940,321 shares of the healthcare product maker’s stock valued at $1,463,680,000 after buying an additional 330,844 shares during the period. Institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on ABT. Royal Bank of Canada restated an “outperform” rating and issued a $135.00 price objective on shares of Abbott Laboratories in a report on Tuesday, January 21st. Barclays reaffirmed an “overweight” rating and issued a $158.00 price objective (up previously from $149.00) on shares of Abbott Laboratories in a research note on Monday, January 27th. Bank of America boosted their price target on Abbott Laboratories from $133.00 to $150.00 and gave the stock a “buy” rating in a research report on Monday, March 10th. Citigroup raised their price objective on Abbott Laboratories from $135.00 to $160.00 and gave the company a “buy” rating in a research note on Tuesday, March 4th. Finally, StockNews.com downgraded Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 12th. Four investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average price target of $137.94.

Abbott Laboratories Trading Up 0.7 %

ABT stock opened at $127.78 on Tuesday. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. The firm has a market cap of $221.61 billion, a P/E ratio of 16.70, a P/E/G ratio of 2.52 and a beta of 0.80. Abbott Laboratories has a 1-year low of $99.71 and a 1-year high of $141.23. The business’s 50 day moving average is $130.67 and its 200-day moving average is $121.51.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.34. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The firm had revenue of $10.97 billion during the quarter, compared to analyst estimates of $11.03 billion. During the same period in the prior year, the company posted $1.19 earnings per share. The business’s revenue for the quarter was up 7.2% compared to the same quarter last year. Equities analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be issued a dividend of $0.59 per share. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.85%. Abbott Laboratories’s dividend payout ratio is 30.85%.

Insiders Place Their Bets

In other news, SVP Eric Shroff sold 562 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total transaction of $77,651.54. Following the transaction, the senior vice president now directly owns 31,970 shares in the company, valued at approximately $4,417,294.90. This represents a 1.73 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Andrea F. Wainer sold 949 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $138.17, for a total transaction of $131,123.33. Following the completion of the transaction, the executive vice president now owns 74,381 shares of the company’s stock, valued at $10,277,222.77. This trade represents a 1.26 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 116,449 shares of company stock valued at $15,463,316. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.